Last reviewed · How we verify
NCT06584227: ACPC
Adebrelimab and Chidamide for Pancreatic Cancer
Phase 2 trial testing Adebrelimab and Chidamide Combined with Gemcitabine and S1 in Pancreatic Cancer, Adult in 45 participants. Currently enrolling.
10 July 2026
Quick facts
| Lead sponsor | Liu Xiufeng |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 10 September 2024 |
| Primary completion | 10 July 2026 |
| Estimated completion | 10 May 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Adebrelimab and Chidamide Combined with Gemcitabine and S1 — full drug profile →
Conditions studied
- Pancreatic Cancer, Adult — all drugs for Pancreatic Cancer, Adult →
Sponsor
Liu Xiufeng — full company profile →
Who can join
Adults 18 to 75, any sex, with Pancreatic Cancer, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pancreatic cancer is a kind of digestive system tumor with high malignant degree and poor prognosis. Most patients with pancreatic cancer are locally advanced or have distant metastases at the time of diagnosis, so it is extremely important to find effective drugs to control tumor metastasis. The primary treatment regimen for advanced pancreatic cancer remains chemotherapy, which results in a median survival time of only 8 to 12 months. Therefore, there is an urgent need to explore new combination therapies to extend survival. Therefore, this study aims to evaluate the efficacy and safety of Adebrelimab and Chidamide in Combination with Gemcitabine and S1 as first-line treatment for locally advanced or metastatic pancreatic cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06584227
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer, Adult
Currently open trials in the same condition.
- NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel · recruiting
- NCT06852014 — Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticod · NA · recruiting
- NCT06388967 — Pancreatic Cancer Detection Consortium · recruiting
- NCT06822413 — Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis · recruiting
- NCT06800469 — Gut Microbiota Analysis in Patients Undergoing Duodencephalopancreasectomy for Pancreatic Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06584227 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liu Xiufeng
- Last refreshed: 8 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06584227.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing